Invex Therapeutics is a pioneering biopharmaceutical company listed on the Australian Securities Exchange (ASX:IXC) with a unique focus on repurposing the approved drug Exenatide for neurological conditions. The company has trademarked its repurposed drug as Presendin™, primarily targeting conditions associated with raised intracranial pressure, such as Idiopathic Intracranial Hypertension (IIH), acute stroke, and traumatic brain injury.
The company’s strategic approach centers on leveraging an existing, approved pharmaceutical compound to develop innovative treatments for challenging neurological disorders. By repurposing Exenatide, Invex Therapeutics aims to provide more effective therapeutic options for patients suffering from conditions that currently have limited treatment alternatives. Their initial clinical development efforts have been concentrated on Idiopathic Intracranial Hypertension, demonstrating a targeted and focused research strategy.
Invex Therapeutics has established a robust network of partnerships with academic and medical institutions, including the University of Birmingham, University Hospitals Birmingham NHS Foundation Trust, and Premier Research. These collaborations underscore the company’s commitment to rigorous scientific research and clinical development. By combining innovative drug repurposing techniques with strategic partnerships, Invex Therapeutics is positioning itself as a forward-thinking biopharmaceutical company dedicated to advancing neurological treatment options.
Join +20,000 subscribers receiving alerts.
Join thousands of investors who rely on StockWire X for timely, accurate market intelligence.
StockWire X delivers fast, reliable, and actionable insights into significant developments across global markets, with coverage spanning technology, biotechnology, healthcare, financials, and emerging industries. Our mission is to provide clear, data-driven content that empowers investors to identify opportunities and make informed decisions ahead of the market.
Our network spans key financial and investment hubs worldwide, ensuring subscribers receive timely updates on market-moving announcements, news, macroeconomic trends, and corporate developments.
Use of Technology
We harness advanced technologies to enhance the speed, accuracy, and relevance of our reporting.
While technology accelerates our workflow, every piece of content is selected, validated, and published by human professionals, in accordance with best practices for accuracy, transparency, and investor value. This hybrid approach ensures speed without compromising editorial integrity.
Feedback and Accuracy
We are committed to accuracy and fairness in our reporting. If you believe any information we have published is inaccurate, incomplete, or misleading, please contact us at admin@stockwirex.com so we can review and address the matter promptly.
StockWire X provides readers with access to market news, educational content, and commentary from financial services professionals, industry experts, and companies (“Contributors”).
StockWire X does not hold an Australian Financial Services Licence (AFSL) and relies on the exemption available under section 911A(2)(eb) of the Corporations Act 2001 (Cth) in respect of any financial product advice provided.
Any advice or information published by StockWire X is general in nature only and has been prepared without taking into account your personal objectives, financial situation, or needs. Before acting on any information, you should consider whether it is appropriate for your circumstances and seek independent, licensed financial advice. You should also obtain and read any relevant Product Disclosure Statement (PDS) or other offer document before making an investment decision.
StockWire X makes no guarantee as to the accuracy, completeness, or timeliness of the information provided, and accepts no responsibility for any loss arising from reliance on it. All content is published in good faith for informational purposes only.
StockWire X may have commercial relationships with some contributors or companies mentioned in our content. Any such relationships will be disclosed where relevant.
If you believe any information we have published is inaccurate, incomplete, or misleading, please contact us at admin@stockwirex.com so we can review and address the matter promptly.
